245 related articles for article (PubMed ID: 12920395)
1. Enzyme replacement therapy in Fabry disease: clinical implications.
Breunig F; Knoll A; Wanner C
Curr Opin Nephrol Hypertens; 2003 Sep; 12(5):491-5. PubMed ID: 12920395
[TBL] [Abstract][Full Text] [Related]
2. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
3. Fabry disease: recent advances in enzyme replacement therapy.
Germain DP
Expert Opin Investig Drugs; 2002 Oct; 11(10):1467-76. PubMed ID: 12387706
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
Mignani R; Cagnoli L
J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.
Desnick RJ; Brady R; Barranger J; Collins AJ; Germain DP; Goldman M; Grabowski G; Packman S; Wilcox WR
Ann Intern Med; 2003 Feb; 138(4):338-46. PubMed ID: 12585833
[TBL] [Abstract][Full Text] [Related]
8. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
9. [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].
Rivera Gallego A; López Rodríguez M; Barbado Hernández FJ; Barba Romero MA; García de Lorenzo Y Mateos A; Pintos Morelle G;
Med Clin (Barc); 2006 Oct; 127(13):481-4. PubMed ID: 17043001
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease.
Kizhner T; Azulay Y; Hainrichson M; Tekoah Y; Arvatz G; Shulman A; Ruderfer I; Aviezer D; Shaaltiel Y
Mol Genet Metab; 2015 Feb; 114(2):259-67. PubMed ID: 25155442
[TBL] [Abstract][Full Text] [Related]
11. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
12. [Management of Fabry disease].
Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
[TBL] [Abstract][Full Text] [Related]
13. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Banikazemi M; Ullman T; Desnick RJ
Mol Genet Metab; 2005 Aug; 85(4):255-9. PubMed ID: 15939645
[TBL] [Abstract][Full Text] [Related]
15. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
16. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
18. Fabry disease - Vascular manifestations.
Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
[TBL] [Abstract][Full Text] [Related]
19. Fabry disease: Review and experience during newborn screening.
Hsu TR; Niu DM
Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
[TBL] [Abstract][Full Text] [Related]
20. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.
Mills K; Vellodi A; Morris P; Cooper D; Morris M; Young E; Winchester B
Eur J Pediatr; 2004 Oct; 163(10):595-603. PubMed ID: 15243806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
